0 8 Monocyte Monocyte NNP 9 15 arrest arrest NN 16 19 and and CC 20 34 transmigration transmigration NN 35 37 on on IN 38 46 inflamed inflamed JJ 47 58 endothelium endothelium NN 59 61 in in IN 62 67 shear shear NN 68 72 flow flow NN 73 75 is be VBZ 76 85 inhibited inhibit VBN 86 88 by by IN 89 108 adenovirus-mediated adenovirus-mediated JJ 109 113 gene gene NN 114 122 transfer transfer NN 123 125 of of IN 126 139 IkappaB-alpha IkappaB-alpha NNP 139 140 . . . 142 154 Mobilization mobilization NN 155 157 of of IN 158 165 nuclear nuclear JJ 166 179 factor-kappaB factor-kappaB NNP 180 181 ( ( ( 181 190 NF-kappaB NF-kappaB NNP 190 191 ) ) ) 192 201 activates activate VBZ 202 215 transcription transcription NN 216 218 of of IN 219 224 genes gene NNS 225 233 encoding encode VBG 234 245 endothelial endothelial JJ 246 254 adhesion adhesion NN 255 264 molecules molecule NNS 265 268 and and CC 269 279 chemokines chemokine NNS 280 284 that that WDT 285 295 contribute contribute VBP 296 298 to to TO 299 307 monocyte monocyte NN 308 320 infiltration infiltration NN 321 329 critical critical JJ 330 332 in in IN 333 346 atherogenesis atherogenesis NN 346 347 . . . 348 358 Inhibition Inhibition NNP 359 361 of of IN 362 371 NF-kappaB NF-kappaB NNP 372 375 has have VBZ 376 380 been be VBN 381 389 achieved achieve VBN 390 392 by by IN 393 408 pharmacological pharmacological JJ 409 412 and and CC 413 420 genetic genetic JJ 421 431 approaches approach NNS 431 432 ; ; : 433 440 however however RB 440 441 , , , 442 450 monocyte monocyte NN 451 463 interactions interaction NNS 464 468 with with IN 469 478 activated activate VBN 479 490 endothelium endothelium NN 491 493 in in IN 494 499 shear shear NN 500 504 flow flow NN 505 514 following follow VBG 515 519 gene gene NN 520 528 transfer transfer NN 529 531 of of IN 532 535 the the DT 536 545 NF-kappaB NF-kappaB NNP 546 555 inhibitor inhibitor NN 556 569 IkappaB-alpha IkappaB-alpha NNP 570 574 have have VBP 575 578 not not RB 579 583 been be VBN 584 591 studied study VBN 591 592 . . . 593 595 We we PRP 596 601 found find VBD 602 606 that that IN 607 621 overexpression overexpression NN 622 624 of of IN 625 638 IkappaB-alpha IkappaB-alpha NNP 639 641 in in IN 642 653 endothelial endothelial JJ 654 659 cells cell NNS 660 665 using use VBG 666 667 a a DT 668 679 recombinant recombinant JJ 680 690 adenovirus adenovirus NN 691 700 prevented prevent VBD 701 706 tumor tumor NN 707 715 necrosis necrosis NN 716 728 factor-alpha factor-alpha NN 729 730 ( ( ( 730 748 TNF-alpha)-induced tnf-alpha)-induced JJ 749 760 degradation degradation NN 761 763 of of IN 764 777 IkappaB-alpha IkappaB-alpha NNP 778 781 and and CC 782 792 suppressed suppress VBD 793 796 the the DT 797 809 upregulation upregulation NN 810 812 of of IN 813 821 vascular vascular JJ 822 826 cell cell NN 827 835 adhesion adhesion NN 836 846 molecule-1 molecule-1 NN 847 848 ( ( ( 848 854 VCAM-1 vcam-1 NN 854 855 ) ) ) 855 856 , , , 857 870 intercellular intercellular JJ 871 879 adhesion adhesion NN 880 890 molecule-1 molecule-1 NN 891 892 ( ( ( 892 898 ICAM-1 icam-1 NN 898 899 ) ) ) 899 900 , , , 901 904 and and CC 905 915 E-selectin E-selectin NNP 916 920 mRNA mRNA NNP 921 924 and and CC 925 932 surface surface NN 933 940 protein protein NN 941 951 expression expression NN 952 955 and and CC 956 959 the the DT 960 972 upregulation upregulation NN 973 975 of of IN 976 987 transcripts transcript NNS 988 991 for for IN 992 995 the the DT 996 1006 chemokines chemokine NNS 1007 1015 monocyte monocyte NN 1016 1031 chemoattractant chemoattractant NN 1032 1039 protein protein NN 1040 1041 1 1 CD 1042 1043 ( ( ( 1043 1048 MCP-1 mcp-1 NN 1048 1049 ) ) ) 1050 1053 and and CC 1054 1068 growth-related growth-related JJ 1069 1083 activity-alpha activity-alpha NN 1084 1085 ( ( ( 1085 1094 GRO-alpha GRO-alpha NNP 1094 1095 ) ) ) 1096 1098 by by IN 1099 1108 TNF-alpha TNF-alpha NNP 1108 1109 . . . 1110 1114 This this DT 1115 1118 was be VBD 1119 1129 associated associate VBN 1130 1134 with with IN 1135 1136 a a DT 1137 1146 reduction reduction NN 1147 1149 in in IN 1150 1161 endothelial endothelial JJ 1162 1167 MCP-1 mcp-1 NN 1168 1177 secretion secretion NN 1178 1181 and and CC 1182 1191 GRO-alpha GRO-alpha NNP 1192 1206 immobilization immobilization NN 1206 1207 . . . 1208 1216 Adhesion Adhesion NNP 1217 1223 assays assay NNS 1224 1229 under under IN 1230 1243 physiological physiological JJ 1244 1249 shear shear NN 1250 1254 flow flow NN 1255 1265 conditions condition NNS 1266 1272 showed show VBD 1273 1277 that that IN 1278 1282 firm firm JJ 1283 1289 arrest arrest NN 1289 1290 , , , 1291 1300 spreading spreading NN 1300 1301 , , , 1302 1305 and and CC 1306 1320 transmigration transmigration NN 1321 1323 of of IN 1324 1333 monocytes monocyte NNS 1334 1336 on on IN 1337 1356 TNF-alpha-activated tnf-alpha-activated JJ 1357 1368 endothelium endothelium NN 1369 1372 was be VBD 1373 1381 markedly markedly RB 1382 1391 inhibited inhibit VBN 1392 1394 by by IN 1395 1408 IkappaB-alpha IkappaB-alpha NNP 1409 1423 overexpression overexpression NN 1423 1424 . . . 1425 1435 Inhibition Inhibition NNP 1436 1440 with with IN 1441 1451 monoclonal monoclonal JJ 1452 1462 antibodies antibody NNS 1463 1466 and and CC 1467 1474 peptide peptide NN 1475 1486 antagonists antagonist NNS 1487 1495 inferred infer VBD 1496 1500 that that IN 1501 1505 this this DT 1506 1509 was be VBD 1510 1513 due due JJ 1514 1516 to to TO 1517 1524 reduced reduce VBN 1525 1535 expression expression NN 1536 1538 of of IN 1539 1541 Ig ig NN 1542 1550 integrin integrin NN 1551 1557 ligand ligand NN 1558 1560 as as RB 1561 1565 well well RB 1566 1568 as as IN 1569 1571 of of IN 1572 1582 chemokines chemokine NNS 1583 1595 specifically specifically RB 1596 1604 involved involve VBN 1605 1607 in in IN 1608 1613 these these DT 1614 1620 events event NNS 1620 1621 . . . 1622 1624 In in IN 1625 1633 contrast contrast NN 1633 1634 , , , 1635 1642 rolling rolling NN 1643 1645 of of IN 1646 1655 monocytes monocyte NNS 1656 1659 was be VBD 1660 1669 increased increase VBN 1670 1672 by by IN 1673 1686 IkappaB-alpha IkappaB-alpha NNP 1687 1695 transfer transfer NN 1696 1699 and and CC 1700 1703 was be VBD 1704 1710 partly partly RB 1711 1719 mediated mediate VBN 1720 1722 by by IN 1723 1733 P-selectin P-selectin NNP 1733 1734 ; ; : 1735 1742 however however RB 1742 1743 , , , 1744 1746 it it PRP 1747 1755 appeared appear VBD 1756 1758 to to TO 1759 1761 be be VB 1762 1772 unaffected unaffected JJ 1773 1775 by by IN 1776 1779 the the DT 1780 1790 inhibition inhibition NN 1791 1793 of of IN 1794 1804 E-selectin E-selectin NNP 1805 1814 induction induction NN 1814 1815 . . . 1816 1820 Thus thus RB 1820 1821 , , , 1822 1825 our our PRP$ 1826 1830 data datum NNS 1831 1838 provide provide VBP 1839 1844 novel novel JJ 1845 1853 evidence evidence NN 1854 1858 that that IN 1859 1868 selective selective JJ 1869 1879 modulation modulation NN 1880 1882 of of IN 1883 1892 NF-kappaB NF-kappaB NNP 1893 1895 by by IN 1896 1906 adenoviral adenoviral JJ 1907 1915 transfer transfer NN 1916 1918 of of IN 1919 1932 IkappaB-alpha IkappaB-alpha NNP 1933 1940 impairs impair VBZ 1941 1944 the the DT 1945 1955 expression expression NN 1956 1958 of of IN 1959 1967 multiple multiple JJ 1968 1979 endothelial endothelial JJ 1980 1984 gene gene NN 1985 1993 products product NNS 1994 2002 required require VBN 2003 2006 for for IN 2007 2017 subsequent subsequent JJ 2018 2026 monocyte monocyte NN 2027 2033 arrest arrest NN 2034 2037 and and CC 2038 2048 emigration emigration NN 2049 2051 in in IN 2052 2057 shear shear NN 2058 2062 flow flow NN 2063 2066 and and CC 2067 2071 thus thus RB 2072 2075 for for IN 2076 2084 monocyte monocyte NN 2085 2097 infiltration infiltration NN 2098 2100 in in IN 2101 2116 atherosclerotic atherosclerotic JJ 2117 2124 plaques plaque NNS 2124 2125 . . .